The confusion has led some authors to conclude that MYB is unlikely to be an important driver oncogene in ACC tumors [18, 19] or even that the fusion partner NFIB plays a more important functional role than expected [20]. This evidence concerns the gene NFIB and adrenal cortex carcinoma.